Day One Biopharmaceuticals Inc (DAWN)

Currency in USD
21.53
+0.04(+0.19%)
Closed·
Showing Day One Biopharmaceuticals historical data. For real-time data please try another search
Fair Value
Day's Range
21.4921.53
52 wk Range
5.6421.53
Key Statistics
Prev. Close
21.53
Open
21.5
Day's Range
21.49-21.53
52 wk Range
5.64-21.53
Volume
2.99M
Average Volume (3m)
3.99M
1-Year Change
178.1654%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DAWN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Currently not supported.
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.
Show more

Day One Biopharmaceuticals Inc Earnings Call Summary for Q3/2025

  • Day One Biopharmaceuticals reported Q3 2025 EPS of -$0.19 (beating -$0.29 forecast) and revenue of $39.8M (exceeding $38.19M forecast), despite stock declining 0.14% in regular trading.
  • The company raised full-year 2025 revenue guidance to $145-$150M following a 15% quarter-over-quarter increase in net product revenue to $38.5M, driven by OJEMDA's commercial success.
  • Key operational achievements include an 18% increase in total prescriptions and 20% rise in new patient starts, with OJEMDA revenue exceeding combined cost of sales and SG&A for the first time.
  • Despite positive performance, the stock remains near its 52-week low of $5.64, reflecting investor caution amid broader market conditions affecting the biotech sector.
  • The company maintains a strong financial position with $451.6M in cash reserves and no debt, while focusing on pipeline advancement and establishing OJEMDA as a standard of care.
Last Updated: 2025-11-04, 05:48 p/m
Read Full Transcript

Earnings

Latest Release
Aug 11, 2026
EPS / Forecast
-- / -0.15
Revenue / Forecast
-- / 57.32M
EPS Revisions
Last 90 days

DAWN Income Statement

Compare DAWN to Peers and Sector

Metrics to compare
DAWN
Peers
Sector
Relationship
P/E Ratio
0.0x0.0x−0.4x
PEG Ratio
0.000.000.00
Price/Book
0.0x0.0x2.6x
Price / LTM Sales
0.0x0.0x3.0x
Upside (Analyst Target)
0.0%0.0%47.5%
Fair Value Upside
Unlock0.0%6.7%Unlock

People Also Watch

104.000
ACS
+1.96%
59.300
IDR
0.00%
3.7350
SABE
+0.24%
178.11
GATX
+0.45%
14.97
FDMT
+1.84%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.